Olema Pharmaceuticals, Inc.
OLMANASDAQHealthcareBiotechnology
Previous close
$10.69
−$0.21 · -1.93%
OLMA company overview
GoAI snapshot
AI-powered factor overview
GoAI score
Sell
Trim exposure — unfavorable risk-reward
Valuation
38
Expensive
Momentum
27
Weakening
Sentiment
60
Mixed
Risk resilience
25
High Risk
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
AI-generated, informational only, and not investment advice.
Company profile
Company websiteOlema Pharmaceuticals, Inc., a biopharmaceutical enterprise in the clinical development stage, is dedicated to discovering, advancing, and commercializing therapeutic solutions for women's oncology. Headquartered in San Francisco, California, the company was established in 2006 and rebranded from CombiThera, Inc. in March 2009. Its most promising investigational compound, OP-1250, an estrogen receptor (ER) antagonist and selective ER degrader, is presently undergoing Phase 1/2 clinical evaluations. This drug candidate is being assessed for its efficacy in managing recurrent, locally advanced, or metastatic breast cancer that expresses estrogen receptors but is negative for human epidermal growth factor receptor 2.
- Industry
- Biotechnology
- Sector
- Healthcare
- Headquarters
- US
- CEO
- Sean Bohen
- Listed since
- Nov 19, 2020
- Employees
- 150
Market position
Day range
Current $10.69
52-week range
Current $10.69
- Open
- $10.91
- Previous close
- $10.90
- Volume
- 748.7K
- 0.58× average
- Average volume
- 1.3M
- Average daily volume
- Market cap
- 933.74M USD
- Beta
- 2.01
- Market reference 1
- 50-day average
- $11.2836
- -5.26% below average
- 200-day average
- $17.6218
- -39.34% below average
Financials
Financial snapshot
Latest / TTMValuation & yield
- Enterprise value
- 2.13B USD
- EV / EBITDA
- -13.14×
- Earnings yield
- -7.47%
- Free cash flow yield
- -6.75%
Profitability & efficiency
- Return on equity
- -33.95%
- Return on assets
- -30.45%
- Return on invested capital
- -37.02%
Financial health
- Current ratio
- 9.95×
- Altman Z-score
- 7.59
- Piotroski F-score
- 2 of 9
Earnings
- Latest fiscal-year EPS
- -1.87
- FY2025
- Latest fiscal-year revenue
- 0 USD
- FY2025
- Next fiscal-year EPS consensus
- -2.39
- FY2026 · 6 analysts
- Next fiscal-year revenue consensus
- 2.25M USD
- FY2026 · 6 analysts
Annual EPS trend
Reported history and fiscal-year consensus
Annual revenue trend
Reported history and fiscal-year consensus
Analyst ratings
Third-party consensus; not a GoAI recommendation.
Recent analyst actions
OLMA peers
ETFs holding OLMA
Funds reporting this stock among their holdings, ordered by reported position size.
State Street SPDR S&P Biotech ETFXBI31.08M0.27%11.39B USD0.35%$165.73+1.44%
Vanguard Morningstar Total Stock Market ETFVTI29.9M0.00%2.3T USD0.03%$378.24+0.44%
iShares Russell 2000 ETFIWM21.96M0.03%81.62B USD0.19%$299.96+0.77%
Vanguard Extended Market ETFVXF7.48M0.01%93.7B USD0.05%$245.53+0.82%
iShares Russell 2000 Value ETFIWN6.63M0.05%14.66B USD0.24%$224.81+0.45%
iShares Biotechnology ETFIBB5.72M0.05%10.75B USD0.44%$213.56+1.29%
Vanguard Russell 2000 ETFVTWO5.03M0.03%17.4B USD0.06%$121.25+0.74%
Fidelity Enhanced Small Cap ETFFESM4.18M0.06%6.03B USD0.28%$47.94+0.80%State Street SPDR S&P Biotech ETFXBI- Market value
- 31.08M
- Weight
- 0.27%
- AUM
- 11.39B USD
- Expense ratio
- 0.35%
- Price / 1D
- $165.73+1.44%
Vanguard Morningstar Total Stock Market ETFVTI- Market value
- 29.9M
- Weight
- 0.00%
- AUM
- 2.3T USD
- Expense ratio
- 0.03%
- Price / 1D
- $378.24+0.44%
iShares Russell 2000 ETFIWM- Market value
- 21.96M
- Weight
- 0.03%
- AUM
- 81.62B USD
- Expense ratio
- 0.19%
- Price / 1D
- $299.96+0.77%
Vanguard Extended Market ETFVXF- Market value
- 7.48M
- Weight
- 0.01%
- AUM
- 93.7B USD
- Expense ratio
- 0.05%
- Price / 1D
- $245.53+0.82%
iShares Russell 2000 Value ETFIWN- Market value
- 6.63M
- Weight
- 0.05%
- AUM
- 14.66B USD
- Expense ratio
- 0.24%
- Price / 1D
- $224.81+0.45%
iShares Biotechnology ETFIBB- Market value
- 5.72M
- Weight
- 0.05%
- AUM
- 10.75B USD
- Expense ratio
- 0.44%
- Price / 1D
- $213.56+1.29%
Vanguard Russell 2000 ETFVTWO- Market value
- 5.03M
- Weight
- 0.03%
- AUM
- 17.4B USD
- Expense ratio
- 0.06%
- Price / 1D
- $121.25+0.74%
Fidelity Enhanced Small Cap ETFFESM- Market value
- 4.18M
- Weight
- 0.06%
- AUM
- 6.03B USD
- Expense ratio
- 0.28%
- Price / 1D
- $47.94+0.80%
Continue in GoAI
Research OLMAresearch.disclaimer